Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method

BACKGROUND: With the increasing use of immune checkpoint inhibitors, tumor mutation burden (TMB) assessment is now routinely included in reports generated from targeted sequencing with large gene panels; however, not all patients require comprehensive profiling with large panels. Our study aims to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yuan, Li, Yuli, Wang, Weiya, Lizaso, Analyn, Hou, Ting, Jiang, Lili, Huang, Meijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082297/
https://www.ncbi.nlm.nih.gov/pubmed/32206555
http://dx.doi.org/10.21037/tlcr.2019.12.27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082297/
https://www.ncbi.nlm.nih.gov/pubmed/32206555
http://dx.doi.org/10.21037/tlcr.2019.12.27

Ejemplares similares